Companies Tvardi Therapeutics, Inc.
Tvardi Therapeutics CEO salary & total pay, FY2025: $3.1M
Tvardi Therapeutics (CARA) CEO salary, fiscal 2025: Imran Alibhai was paid a salary of $620,000 and $3,116,090 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Tvardi Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Imran Alibhai's complete compensation dossier
A PDF and a CSV sent to your email: Imran Alibhai's pay in every fiscal year Tvardi Therapeutics, Inc. reported it, line by line, with Imran Alibhai's equity grants and Tvardi Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $2,922,469FY2023
- $857,330FY2024
- $3,116,090FY2025
CEO total pay was $3,116,090 in fiscal 2025, up from $857,330 in fiscal 2024.
FY2025: salary $620,000 · option awards $2,173,903
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Imran Alibhai | $620,000 | — | — | $2,173,903 | $289,850 | — | $32,337 | $3,116,090 |
| Chief Executive Officer and Director | ||||||||
| Christopher Posner | 203,933 | — | — | — | — | — | 2,366,327 | 2,570,260 |
| Former (Cara) President and Chief Executive Officer | ||||||||
| John Kauh | 500,000 | 0 | — | 454,315 | 170,000 | — | 32,337 | 1,156,652 |
| Chief Medical Officer | ||||||||
| Dan Conn | 450,000 | — | — | 536,451 | 153,000 | — | — | 1,139,451 |
| Chief Financial Officer | ||||||||
| Ryan Maynard | 134,013 | — | — | — | — | — | 997,899 | 1,131,912 |
| Former (Cara) Chief Financial Officer | ||||||||
| Scott Terrillion | 129,935 | — | — | — | — | — | 982,503 | 1,112,438 |
| Former (Cara) General Counsel, Secretary and Chief Compliance Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Imran Alibhai | $3,116,090 | $857,330 | — | ↑ +2,258,760 |
| Christopher Posner | 2,570,260 | 1,065,879 | 2,922,469 | ↑ +1,504,381 |
| John Kauh | 1,156,652 | 565,830 | — | ↑ +590,822 |
| Dan Conn | 1,139,451 | 552,595 | — | ↑ +586,856 |
| Ryan Maynard | 1,131,912 | 607,279 | 1,243,857 | ↑ +524,633 |
| Scott Terrillion | 1,112,438 | 592,857 | — | ↑ +519,581 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company designs its compensation program to attract, retain, and reward talented executives while promoting company success and aligning executive incentives with the long-term interests of stockholders. The program evaluates market comparables, individual performance, and the desire to motivate short- and long-term results.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc and Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Dan Conn | Option | 87,198 | 1,856 | 4.7 | — |
| Dan Conn | Option | — | 43,547 | 17.04 | — |
| Dan Conn | Option | — | 17,500 | 4.2 | — |
| Imran Alibhai | Option | — | 182,320 | 17.04 | — |
| Imran Alibhai | Option | — | 47,500 | 4.2 | — |
| Imran Alibhai | Option | 207,881 | — | 0.67 | — |
| Imran Alibhai | Option | 2,012 | — | 0.67 | — |
| Imran Alibhai | Option | 160,940 | — | 4.7 | — |
| John Kauh | Option | 53,994 | 20,056 | 6.11 | — |
| John Kauh | Option | — | 36,210 | 17.04 | — |
| John Kauh | Option | — | 17,500 | 4.2 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Susan Shiff, Ph.DIndependent · Audit · Compensation · Nominating and Corporate Governance | $24,962 | — | $131,004 | — | $109,021 | $264,987 |
| Martin VogelbaumIndependent · Departed during FY | 34,945 | 0 | — | — | 218,067 | 253,012 |
| Sujal ShahIndependent · Compensation (Chair) | 53,157 | — | 131,004 | — | 0 | 184,161 |
| Michael S. WyzgaIndependent · Audit (Chair) | 39,558 | — | 131,004 | — | 0 | 170,562 |
| Shaheen Wirk, M.DIndependent · Departed during FY | 27,585 | — | 131,004 | — | 0 | 158,589 |
| Wallace L. Hall JrIndependent · Audit · Compensation | 24,521 | — | 131,004 | — | 0 | 155,525 |
| Cynthia SmithIndependent · Governance (Chair) | 24,170 | — | 131,004 | — | 0 | 155,174 |
| Jeffrey L. Ives, Ph.DIndependent · Departed during FY | 21,113 | 0 | 0 | — | 109,021 | 130,134 |
| Helen M. BoudreauIndependent · Departed during FY | 20,385 | 0 | — | — | 109,021 | 129,406 |
| Lisa von MoltkeIndependent · Departed during FY | 16,016 | 0 | — | — | 109,021 | 125,037 |
| Imran Alibhai, Ph.DEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $286,412 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $654,151 |
| Total cost of the board | $940,563 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Tvardi Therapeutics as a peer
Companies that benchmark against CARA
1 company names CARA as a compensation peer
Each company listed discloses CARA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CARA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Tvardi Therapeutics, Inc. | 2025 | Imran Alibhai | $620,000 | — | $2,173,903 | $289,850 | $3,116,090 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 3,482,265 | 161,795 | 16,451 | 95.13% | Passed |
| 2024 | 2024-06-04 | 16,277,985 | 10,660,228 | 71,329 | 60.27% | Passed |
| 2023 | 2023-06-01 | 26,928,795 | 7,711,887 | 71,219 | 77.58% | Passed |
| 2022 | 2022-06-02 | 27,112,737 | 7,510,336 | 56,880 | 78.18% | Passed |
| 2021 | 2021-06-03 | 28,190,965 | 979,010 | 115,787 | 96.26% | Passed |
| 2020 | 2020-06-04 | 26,434,667 | 480,766 | 265,526 | 97.25% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 95.13%a |
| 2024 | 2024-06-04 | 60.27%b |
| 2023 | 2023-06-01 | 77.58%c |
a. Approved under the standard stated in the filing — “This proposal, commonly referred to as the "say-on-pay" vote, must receive FOR votes from the holders of a majority of the shares present at the meeting (by virtual attendance) or represented by proxy and entitled to vote on the matter. || Abstentions: If you "Abstain" from voting, it will have the same effect as an "Against" vote.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposals 2 and 3 and will have the same effect as "Against" votes.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total for Proposals 2 and 3, and will have the same effect as "Against" votes.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Michael S. Wyzga | Director | 2026-06-09 | A | 6,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Wallace L. Hall Jr | Director | 2026-06-09 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sujal Shah | Director | 2026-06-09 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Smith | Director | 2026-06-09 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Susan Ph.D. Shiff | Director | 2026-06-09 | A | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (28 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Imran Alibhai. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 3,116,090. View filing ↗
- Section 01, Christopher Posner. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 2,570,260. View filing ↗
- Section 01, John Kauh. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,156,652. View filing ↗
- Section 01, Dan Conn. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,139,451. View filing ↗
- Section 01, Ryan Maynard. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,131,912. View filing ↗
- Section 01, Scott Terrillion. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 28. As printed: 1,112,438. View filing ↗
- Section 08, Susan Shiff, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 264,987. View filing ↗
- Section 08, Martin Vogelbaum. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 253,012. View filing ↗
- Section 08, Sujal Shah. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 184,161. View filing ↗
- Section 08, Michael S. Wyzga. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 170,562. View filing ↗
- Section 08, Shaheen Wirk, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 158,589. View filing ↗
- Section 08, Wallace L. Hall Jr. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 155,525. View filing ↗
- Section 08, Cynthia Smith. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 155,174. View filing ↗
- Section 08, Jeffrey L. Ives, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 130,134. View filing ↗
- Section 08, Helen M. Boudreau. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 129,406. View filing ↗
- Section 08, Lisa von Moltke. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 125,037. View filing ↗
- Section 08, Imran Alibhai, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Michael S. Wyzga 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Wallace L. Hall Jr 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sujal Shah 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Smith 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan Ph.D. Shiff 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 95.13% (votes for as printed: 3,482,265). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 60.27% (votes for as printed: 16,277,985). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-02. Item 5.07 · say-on-pay result. As reported: 77.58% (votes for as printed: 26,928,795). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 286,412 + equity 0 + all other 654,151 = 940,563, summed across the director compensation table rows.
- Tvardi Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Tvardi Therapeutics, Inc.'s own proxy. As printed: 3,116,090. View filing ↗